GSK Settles Zantac Lawsuits: A New Chapter for the Controversial Drug
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that certain versions might contain impurities linked to cancer,
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
GlaxoSmithKline (NYSE:GSK) hit a new 52-week high Tuesday as it is currently trading at $53.61, above its previous 52-week high of $53.45 with 1.2 million shares traded as of 12:05 p.m. ET.
The housebuilding section also saw a reduction in profits, but tailwinds for the s ...
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
Brokerages feel that the deal is likely to be EPS-accretive for HUL and investors who have a time horizon of more than a year can hold the stock with a target placed above Rs 2,000 Health Food ...
A global leader in pharmaceuticals, GSK’s mechanical engineers are responsible for projects from the design and installation of manufacturing equipment through to building maintenance and R&D. As ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter ...
This report presents key facts and figures about the British pharmaceutical company GSK, formerly known as GlaxoSmithKline. GSK is one of the world's 10 largest pharmaceutical companies.
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback